104 related articles for article (PubMed ID: 26556688)
1. Genetic variation in IL-1β, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder.
Maciukiewicz M; Marshe VS; Tiwari AK; Fonseka TM; Freeman N; Rotzinger S; Foster JA; Kennedy JL; Kennedy SH; Müller DJ
Pharmacogenomics; 2015 Nov; 16(17):1919-29. PubMed ID: 26556688
[TBL] [Abstract][Full Text] [Related]
2. Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds.
Fornaro M; Rocchi G; Escelsior A; Contini P; Martino M
J Affect Disord; 2013 Mar; 145(3):300-7. PubMed ID: 22981313
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.
Raskin J; Wiltse CG; Siegal A; Sheikh J; Xu J; Dinkel JJ; Rotz BT; Mohs RC
Am J Psychiatry; 2007 Jun; 164(6):900-9. PubMed ID: 17541049
[TBL] [Abstract][Full Text] [Related]
4. BDNF plasma levels variations in major depressed patients receiving duloxetine.
Fornaro M; Escelsior A; Rocchi G; Conio B; Magioncalda P; Marozzi V; Presta A; Sterlini B; Contini P; Amore M; Fornaro P; Martino M
Neurol Sci; 2015 May; 36(5):729-34. PubMed ID: 25501804
[TBL] [Abstract][Full Text] [Related]
5. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
[TBL] [Abstract][Full Text] [Related]
6. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide association studies of placebo and duloxetine response in major depressive disorder.
Maciukiewicz M; Marshe VS; Tiwari AK; Fonseka TM; Freeman N; Kennedy JL; Rotzinger S; Foster JA; Kennedy SH; Müller DJ
Pharmacogenomics J; 2018 May; 18(3):406-412. PubMed ID: 28696415
[TBL] [Abstract][Full Text] [Related]
9. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
Baldwin DS; Loft H; Dragheim M
Eur Neuropsychopharmacol; 2012 Jul; 22(7):482-91. PubMed ID: 22209361
[TBL] [Abstract][Full Text] [Related]
10. The role of genetic variation across IL-1β, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain.
Fonseka TM; Tiwari AK; Gonçalves VF; Lieberman JA; Meltzer HY; Goldstein BI; Kennedy JL; Kennedy SH; Müller DJ
World J Biol Psychiatry; 2015 Jan; 16(1):45-56. PubMed ID: 25560300
[TBL] [Abstract][Full Text] [Related]
11. Effect of duloxetine on changes in serum proinflammatory cytokine levels in patients with major depressive disorder.
Gao W; Gao Y; Xu Y; Liang J; Sun Y; Zhang Y; Shan F; Ge J; Xia Q
BMC Psychiatry; 2024 Jun; 24(1):449. PubMed ID: 38877455
[TBL] [Abstract][Full Text] [Related]
12. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
13. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo.
Robinson M; Oakes TM; Raskin J; Liu P; Shoemaker S; Nelson JC
Am J Geriatr Psychiatry; 2014 Jan; 22(1):34-45. PubMed ID: 24314888
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
15. Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.
Yu JJ; Pei LB; Zhang Y; Wen ZY; Yang JL
J Clin Psychopharmacol; 2015 Aug; 35(4):406-10. PubMed ID: 26066335
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
17. Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
Kagawa S; Mihara K; Suzuki T; Nagai G; Nakamura A; Nemoto K; Kondo T
Neuropsychobiology; 2017; 75(3):145-150. PubMed ID: 29332095
[TBL] [Abstract][Full Text] [Related]
18. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
[TBL] [Abstract][Full Text] [Related]
19. Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response.
Domschke K; Lawford B; Laje G; Berger K; Young R; Morris P; Deckert J; Arolt V; McMahon FJ; Baune BT
Int J Neuropsychopharmacol; 2010 Feb; 13(1):93-101. PubMed ID: 19236730
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
